ERBB2 and breast cancer: Such a therapeutic approach has been adopted in the BOLERO-3 (Breast Cancer Trials of Oral Everolimus) clinical trial, in which the addition of everolimus to trastuzumab and vinorelbine significantly prolonged progression-free survival in patients with HER2+ metastatic breast cancer resistant to trastuzumab, as presented by Dr O’Regan during the 2013 ASCO annual meeting (unpublished observations, Ruth O’Regan).